drugset / Trial / NCT00303589

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

NCT00303589

Phase 2 Completed 313 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelTreatment

Summary

This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h 2)beta-lactam 1500mg iv q8h or 3)'standard care' \[PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin\]. The anticipated time on study treatment is \<3 months and the target sample size is 100-500 individuals.

Timeline

Start
2005-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aztreonam Small molecule
Comparator Ciprofloxacin Small molecule
Comparator FLOXACILLIN Small molecule
Comparator Vancomycin Other / unclassified
Comparator nafcillin Small molecule

Indications

No indication recorded.